The Evaluate Pharma Half-Year Review 2019 summaries the most significant trends across pharma, medtech and biotech

13 August 2019

Evaluate Pharma

Mega-deals mask a significant decline in M&A activity for pharma and medtech 

The Vantage Half-Year Review 2019 summaries the most significant trends across pharma, medtech and biotech in the first half of 2019.

Bristol-Myers Squibb’s $74bn pending purchase Celgene and Abbvie’s $63bn acquisition of Allergan have taken the headlines, positioning 2019 to be a record year for pharma M&A spend, while Verily’s $1bn round of funding in Q1 was the largest ever seen in the medtech.

However, these colossal deals are masking a substantial slowdown in the total number of M&A deals in both pharma and medtech, and pharma doubled down on this trend with a similar drop in licensing activity. Investors remain cautious due to potential US drug reforms and elsewhere the biotech boom appears to be over, except for a couple of isolated bubbles.

Key highlights

  • 2019 set to be a record year for pharma M&A spend, but mega-deals mask wider drop in deal numbers

  • Verily’s $1bn round of funding in Q1 was medtech’s largest ever, but the sector also experienced substantial declining deal numbers

  • Only 8 medtech companies went public during the first half of 2019, but collectively raised $1.3bn

  • Q2 biotech flotations raised $2bn, as investor enthusiasm attracts younger drug developers away from traditional M&A and partnerships

  • Uncertainty around potential US drug price reform continues to be a significant investor concern.

Source

Print

Shareholders

Read more

Pipeline

Read more

Media Center

Read more